Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Chris:
That's because I'm "several" years old - lol - Ann
(to all):
Found this on a Malasia search engine:
http://ask.elibrary.com/login.asp?c=&host=ask%2Eelibrary%2Ecom&script=%2Fgetdoc%2Easp&qu...
Ann
OK - Team - Ann
I'm honored, Cowboyd - Ann
Cowboy:
A refresher:
FDA Initiative and Pharmacogenomics
In a recent release, the FDA announced that pharmaceutical and bio pharmaceutical companies should take into consideration genetic testing during clinical trials and for post approval drug monitoring. Pharmaceutical and bio pharmaceutical companies will need to incorporate genetic testing in their drug discovery, clinical development as well as post drug approval monitoring in the very near future. Leveraging its proprietary ADMIXMAP, MALD/AIM, AIMs, and ultra high throughput SNP screening technologies, DNAPrintTM is strategically positioned to serve the growing compliance and operational needs of pharmaceutical companies.
The FDA estimates that 2.4 million patients had adverse drug reactions in 2000, leading to the deaths of more than 125,000 patients. Adverse drug reactions represent the fourth leading cause of death in the United States.
As part of the FDA’s mandate to reduce the number of deaths caused by adverse drug reactions, on January 31, 2003 the FDA released an initial statement covering new initiatives related to pharmacogenomics. The FDA recognizes that new therapies will be developed because pharmacogenomic tests that can define sub-populations that exhibit a differential response to drug therapies will be available. As a result, the FDA plans to hold a workshop in 2003 to discuss issues involved in the co-development of pharmacogenomics tests and drugs. By mid-2004, the agency plans to issue joint guidance between The Center for Devices and Radiological Health (“CDRH”) and The Center for Drug Evaluation and Research (“CDER”) outlining the regulatory pathway to approval for drug/pharmacogenomic diagnostic combinations. In 2005, the FDA plans to issue guidance on when and how to submit pharmacogenomic information to the agency during the drug development process and clarify when such information will be considered as part of the drug safety evaluation process.
Within the next 12 months we believe there will exist a clear path to market for pharmacogenomic tests linked to drugs. In addition, with greater FDA recognition of pharmacogenomics, the pharmaceutical industry will accelerate its rate of adoption for pharmacogenomics tests.
---------------------------------------------------------------Potential opportunity
Sociopolitical developments indicate a favorable market opportunity for DNAPrintTM’s forensic DNA products. On March 11, 2003 Attorney General John Ashcroft announced that the administration plans to commit $1 billion to DNA testing over the next five years. The money announced by Ashcroft will be used to develop better genetics testing techniques, eliminate DNA backlog of nearly 360,000 cases and provide funds for police departments to use DNA testing more frequently in their investigations, thereby reducing the likelihood of wrongful prosecution and imprisonment.
- Ann
More on Family Tree:
http://www.familytreedna.com/description.html#OxfordConversionKitPlus - Ann
(to all:
Family Tree is liasoned w/DNAPrint:
http://www.familytreedna.com/faqdnaprint.html
(To anyone): - Posted in DNAPrint site:
FDA Initiative and Pharmacogenomics
In a recent release, the FDA announced that pharmaceutical and bio pharmaceutical companies should take into consideration genetic testing during clinical trials and for post approval drug monitoring. Pharmaceutical and bio pharmaceutical companies will need to incorporate genetic testing in their drug discovery, clinical development as well as post drug approval monitoring in the very near future. Leveraging its proprietary ADMIXMAP, MALD/AIM, AIMs, and ultra high throughput SNP screening technologies, DNAPrintTM is strategically positioned to serve the growing compliance and operational needs of pharmaceutical companies.
The FDA estimates that 2.4 million patients had adverse drug reactions in 2000, leading to the deaths of more than 125,000 patients. Adverse drug reactions represent the fourth leading cause of death in the United States.
As part of the FDA’s mandate to reduce the number of deaths caused by adverse drug reactions, on January 31, 2003 the FDA released an initial statement covering new initiatives related to pharmacogenomics. The FDA recognizes that new therapies will be developed because pharmacogenomic tests that can define sub-populations that exhibit a differential response to drug therapies will be available. As a result, the FDA plans to hold a workshop in 2003 to discuss issues involved in the co-development of pharmacogenomics tests and drugs. By mid-2004, the agency plans to issue joint guidance between The Center for Devices and Radiological Health (“CDRH”) and The Center for Drug Evaluation and Research (“CDER”) outlining the regulatory pathway to approval for drug/pharmacogenomic diagnostic combinations. In 2005, the FDA plans to issue guidance on when and how to submit pharmacogenomic information to the agency during the drug development process and clarify when such information will be considered as part of the drug safety evaluation process.
Within the next 12 months we believe there will exist a clear path to market for pharmacogenomic tests linked to drugs. In addition, with greater FDA recognition of pharmacogenomics, the pharmaceutical industry will accelerate its rate of adoption for pharmacogenomics tests.
Ann
Yeah, Dewd - you're Rewd!
Doug:
You are succinct and to the point! - Ann
(Anyone):
How 'bout writing Jeb Bush to see if he's heard of DNAP and directing him to the website, as just one possibility? - Ann
TY, Matt - Ann
I deleted my cookies, then signed in (user name & passwored)and it seemed to work, so far. Got my fingers crossed and clickin' my beads - lol - Ann
Chris:
Sorry to hear that. Mine is now back to normal and hope it stays that way! - Ann
Thank you, Doug. As of today, the problem seems to have been resolved for me. So far, so good. I'm just glad that it wasn't a new format that was going to persist for all of us. - Ann
Patience - I'm not referring to general ads at all. It appeared on my screen yesterday (maybe no one else) - I'm talking about the page that we actually read the posts from, (i.e. this one here) - Ann
Great - it's ok now. - A nice day...Ann
To All:
Is anyone getting the split-page on our message board page/automatic billboard add-ons, right screen. Pretty annoying, elongates subject matter, copy and makes it for harder reading than it used to be, when our copy went across full page. Am I the only one noticing/getting this very recent sneak attack by sponsors or whomever? - Ann
Late Now! Apologize! - Year 2000 - LOL! Jes doin' my best! - I'm entitled to one mistake, aren't I? - Ann
Dec. patent submissions:
http://tampabay.bizjournals.com/tampabay/stories/2000/12/04/daily3.html
Ann
Undated - anyone know if this is old news?
http://ask.elibrary.com/login.asp?c=&host=ask%2Eelibrary%2Ecom&script=%2Fgetdoc%2Easp&qu...
Ann
FDA-Issued Guidance on Pharmacogenomics:
http://www.hum-molgen.de/NewsGen/11-2003/msg15.html
Ann
Wonder if DNAP representation will be there:
http://www.drugdisc.com/europe/default.asp?src=eu706
Ann
Tig:
I posted it, because I wondered if this is the CNN news story you "thought" you heard blurbs re: DNA. - Guess it wasn't. - Ann
Tig:
This CNN story on DNA, dug up for 1/2/04:
http://www.bet.com/articles/0,,c1gb8397-9246,00.html
Ann
Kgarner:
I received this trick a long time ago and was given the solution to it...but, forgot! A lot of help I am! - Ann
DNAWORKS from DNAPRINT:
http://www.familytreedna.com/description.html#dnaworks
Ann
A refresher:
http://www.familytreedna.com/faqdnaprint.html
Ann
Yes, it was, Lookin'
Ann
TY - JEG
Arch:
I've got the ?Boogie Woogie Blues"...Happy New Year to you. We're just into 2004.
Ann
To All My Friends:
http://web.icq.com/friendship/browse_page/1,,16961,00.html
Ann
I believe AOL has some interest/affiliation with Ancestry, since it posts Ancestry billboards and info on it's Welcome Page from time to time. - JMHO - Ann
She typed the name William Iahn in ancestry.com. Under Iahn's file was his marriage to Thelma Theodosia Harold and her death in 1984. Beneath it was an intriguing line:
Don't we have a tie into Ancestry? or am I wrong? - Ann
Reply to all:
Take a look at this story. Father/son reunited after over 50 yrs., thanks to search through Ancestry.com.
http://aolsvc.news.aol.com/news/article.adp?id=20031225161809990001
Ann
Forgive me for getting carried away in this wonderful holiday season, but, here's another animated card to wish all you Christmas cheer!
http://web.icq.com/friendship/browse_page/0,,16959,00.html
My best to all - (don't forget to click on reindeer)
Ann
To All:
I know you've seen this before. But, one more time for those who might have missed it...my very sincerest best Holiday wishes to all! Tony, as Santa, us as the reindeer and Chris "tinkering" with the moon. (Hit each reindeer w/your curser)
Merry Christmas and Happy Holidays to all of the wonderful people on this board! - Ann
http://web.icq.com/shockwave/0,,4845,00.swf
On Tampa Bay and Luchese/DNAP:
http://web.ask.com/redir?bpg=http%3a%2f%2fweb.ask.com%2fweb%3fq%3dabout%2bjack%2bluchese%26o%3d0%26p...
Nite all - Ann